A Phase 4 interventional study of Haloperidol and Ondansetron in Vomiting, Nausea and Abdominal Pain, sponsored by Western Michigan University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by Western Michigan University School of Medicine · Phase 4, Interventional, and Treatment
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
822 studies on the registry are indexed under Nausea; 104 are open to participants now.
This study's enrollment of 60 is below the median of 115 across 703 interventional studies indexed under Nausea.
Browse Nausea studies →Western Michigan University School of Medicine is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride
Drug: Haloperidol
4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride
Drug: Ondansetron
2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
Also known as: Haldol
Ondansetron
Visual Analog Scale (VAS)
Mean change in visual analog scale (VAS) of self-rated nausea severity
Time frame: from enrollment to 30, 60, and 90 minutes after drug administration
Analgesia
Measurement of analgesia graded based on a self-reported validated 10 point visual analog scale (VAS)
Time frame: 0, 30, 60, 90 minutes
Efficacy in marijuana users
Marijuanna use will be documented and quantified
Time frame: Baseline (time 0)
QT prolongation
QT will be measured on the cardiac monitor
Time frame: Baseline (time 0) and 90 minutes
Incidence of side-effects
Inquiry about side effects
Time frame: 0, 30, 60, 90 minutes and 24 hours
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Western Michigan University School of Medicine